Tumor News and Research

RSS

Pancreatic Cancer Action Network, AACR honor NYU School of Medicine's scientist with Fellowship

NYU School of Medicine's Cosimo Commisso, PhD, a postdoctoral fellow in the Department of Biochemistry, is the 2011 recipient of The Pancreatic Cancer Action Network-American Association for Cancer Research Fellowship, a one-year grant designed to support pancreatic cancer research.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Celldex Therapeutics, Inc. today announced that new data on its preclinical therapeutic antibody program, CDX-1127, is being presented in a poster presentation at the 2011 American Association for Cancer Research 102nd Annual Meeting in Orlando, FL.

6 Apr 2011

Under stressful conditions, presence of high levels of HER2 protein causes a decrease in autophagy

Research from The Cancer Institute of New Jersey (CINJ) on biological pathways that govern progression and treatment responsiveness of HER2 positive breast cancer is being presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando this week. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Apr 2011

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Aeterna Zentaris Inc. today announced that a poster on its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131, was presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

Henry Ford performs partial nephrectomy with new, robotically controlled ultrasound probe

Henry Ford Hospital was the first hospital world-wide to use a new, robotically controlled ultrasound probe to help remove a cancerous tumor from a kidney.

6 Apr 2011

Expression of key tumor suppressor protein induces premature aging

Cancer risk increases with age, and scientists have long perceived a possible evolutionary tradeoff between longer lifespan and greater risk of cancer. Now, researchers at Fox Chase Cancer Center find direct evidence for that tradeoff in new data showing that expression of a key tumor suppressor protein induces premature aging in mice.

6 Apr 2011

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Pervasis Therapeutics, Inc. today announced preclinical data showing positive effects of PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, on controlling tumor growth and inhibiting metastases in an animal model of prostate cancer.

6 Apr 2011

Scientists develop new method to identify factors that suppress cancer gene expression

Tumor suppressor genes normally control the growth of cells, but cancer can spring up when these genes are silenced by certain chemical reactions that modify chromosomes.

6 Apr 2011

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Apart from its direct effect on health (such as cardiovascular diseases and diabetes), obesity is increasingly suspected of playing a role in the prognosis of breast cancer and, in particular, its propensity to spread. However, no direct cause and effect relationship had been demonstrated until now. This breakthrough has finally been made through the collaborative work of two teams of researchers from Inserm, CNRS and the Université Paul Sabatier.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Researchers identify genetic anomaly that may drive rare subset of prostate cancers

Researchers at the University of Michigan Comprehensive Cancer Center have identified a genetic anomaly that may drive the aggressive spread of a rare subset of prostate cancers.

5 Apr 2011

Tumor cryoablation coupled with immunotherapy amplifies tumor immunity

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 102nd Annual Meeting 2011 showing that when tumor cryoablation – or the freezing of tumor tissue while preserving tumor-associated antigens – is coupled with immune system modulation, the procedures have the potential to initiate or amplify tumor immunity.

5 Apr 2011

Preliminary discovery may help individualize prostate cancer screening in the future

Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach.

5 Apr 2011

Scientists suggest genetic differences in breast tissue across ethnicities

Scientists from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are working on a series of genetic analyses that suggest the underlying differences among racial groups are present not just in tumors, but in normal tissue as well. Lisa Baumbach, Ph.D., associate research professor, and colleagues will present the full study results at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Tumor News and Research

Pancreatic Cancer Action Network, AACR honor NYU School of Medicine's scientist with Fellowship

Record number of medicines for various cancers in clinical trials

Celldex presents CDX-1127 preclinical data against cancer at AACR meeting

Under stressful conditions, presence of high levels of HER2 protein causes a decrease in autophagy

Aeterna Zentaris presents AEZS-131 data against cancer at AACR meeting

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Henry Ford performs partial nephrectomy with new, robotically controlled ultrasound probe

Expression of key tumor suppressor protein induces premature aging

Pervasis' PVS-30200 study data in prostate cancer presented at AACR meeting

Scientists develop new method to identify factors that suppress cancer gene expression

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Researchers identify genetic anomaly that may drive rare subset of prostate cancers

Tumor cryoablation coupled with immunotherapy amplifies tumor immunity

Preliminary discovery may help individualize prostate cancer screening in the future

Scientists suggest genetic differences in breast tissue across ethnicities

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News